AstraZeneca Acquires Zegfrovy for $1.5 Billion Lung Cancer Market

AstraZeneca PLC (NYSE: AZN) is paying $600 million upfront for global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, with a potential total value of $1.5 billion if development and sales milestones are met. Zegfrovy, approved in the U.S. and China, targets a specific lung cancer patient group, addressing an unmet need. In the Phase III WU-KONG28 trial, it achieved median progression-free survival of 10.3 months compared to 7.5 months for chemotherapy. This acquisition strengthens AstraZeneca's oncology portfolio and could enhance its market position in lung cancer treatment, offering potential benefits for investors.